StockData
Connect Biopharma Holdings Ltd logo

Connect Biopharma Holdings Ltd (CNTB) stock

CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.58−0.06 (-9.98%)

Close on Nov 17, 2026Market cap $36.45MP/E –Yield –

Connect Biopharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Connect Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$69.73M. For fiscal 2025 it was -$57.37M. The highest annual figure on record is -$21.79M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$57.37M–
FY2024Dec 31, 2024-$21.79M–
FY2023Dec 31, 2023-$68.34M–
FY2022Dec 31, 2022-$118.29M–
FY2021Dec 31, 2021-$97.47M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.44M–
Q1 FY2026Mar 31, 2026-$19.44M–
Q4 FY2025Dec 31, 2025-$15.35M–
Q3 FY2025Sep 30, 2025-$17.50M–
Q2 FY2025Jun 30, 2025-$13.25M-196.0%
Q1 FY2025Mar 31, 2025-$11.27M–
Q4 FY2024Dec 31, 2024-$9.46M–
Q3 FY2024Sep 30, 2024-$13.67M–
Q2 FY2024Jun 30, 2024$13.81M–
Q1 FY2024Mar 31, 2024-$12.47M–

More Connect Biopharma figures

See a number that looks wrong?